90. Retinitis pigmentosa Clinical trials / Disease details

Clinical trials : 130 / Drugs : 180 - (DrugBank : 41) / Drug target genes : 49 - Drug target pathways : 109

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04355689 (ClinicalTrials.gov)	September 3, 2020	17/4/2020	Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome	Safety and Efficacy of NPI-001 Tablets Versus Placebo for Treatment of Retinitis Pigmentosa Associated With Usher Syndrome	Usher Syndromes	Drug: NPI-001;Other: Placebo	Nacuity Pharmaceuticals, Inc.	Foundation Fighting Blindness	Recruiting	18 Years	N/A	All	48	Phase 1/Phase 2	Australia
2	NCT03999021 (ClinicalTrials.gov)	June 24, 2019	24/6/2019	FIGHT-RP 1 Extension Study	A Phase 1 Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of N-Acetylcysteine (NAC) in Patients With Retinitis Pigmentosa	Retinitis Pigmentosa	Drug: NAC effervescent tablets	Johns Hopkins University	NULL	Active, not recruiting	18 Years	N/A	All	30	Phase 1	United States
3	NCT03063021 (ClinicalTrials.gov)	February 15, 2017	16/2/2017	The FIGHT-RP1 Study	A Phase 1 Open Label Dose Ranging Study to Assess the Safety and Tolerability of N-Acetylcysteine (NAC) in Patients With Retinitis Pigmentosa (FIGHT-RP1 Study)	Retinitis Pigmentosa	Drug: N-Acetyl Cysteine (NAC)	Johns Hopkins University	NULL	Completed	18 Years	N/A	All	30	Phase 1	United States